IL6 and type 2 diabetes mellitus: Interestingly, patients with type 2 diabetes receiving empagliflozin showed similar gut microbiota alterations with our findings, accompanying with improved glucose metabolism and decreased interleukin-6 (IL-6), that is, depleted taxa of the harmful bacteria of Escherichia, Bilophila, and Hungatella, and enrichment of SCFA-producing bacteria, such as Roseburia and Faecalibacterium (42).